Forbes: Insurers Fret Hepatitis C Pill Costs More Than Obamacare
As health insurance companies reveal much anticipated first-quarter earnings, it’s the unpredictable impact from the five-figure cost of new Hepatitis C treatments that are the subject of as much Wall Street worry as the Affordable Care Act. The cost of a course of treatment has been pegged at more than $80,000. The market is large with the liver disease afflicting more than three million Americans. And there are more Hepatitis C drugs to come. ... Across the industry, the cost of Hepatitis C medications could run more than $1 billion in the first quarter alone (Japsen, 4/17).
Related, earlier KHN story: Biggest Insurer Shocked With Hepatitis C Costs (Hancock, 4/17).
This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from major news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.